🎉 M&A multiples are live!
Check it out!

Argenica Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Argenica Therapeutics and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Argenica Therapeutics Overview

About Argenica Therapeutics

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.


Founded

2019

HQ

Australia
Employees

n/a

Website

argenica.com.au

Financials

LTM Revenue $1.8M

LTM EBITDA n/a

EV

$51.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Argenica Therapeutics Financials

Argenica Therapeutics has a last 12-month revenue of $1.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Argenica Therapeutics achieved revenue of n/a and an EBITDA of -$3.5M.

Argenica Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Argenica Therapeutics valuation multiples based on analyst estimates

Argenica Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$3.0M -$3.5M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$2.6M -$3.0M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Argenica Therapeutics Stock Performance

As of March 17, 2025, Argenica Therapeutics's stock price is AUD 1 (or $0).

Argenica Therapeutics has current market cap of AUD 96.1M (or $60.8M), and EV of AUD 81.0M (or $51.2M).

See Argenica Therapeutics trading valuation data

Argenica Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$51.2M $60.8M XXX XXX XXX XXX $-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Argenica Therapeutics Valuation Multiples

As of March 17, 2025, Argenica Therapeutics has market cap of $60.8M and EV of $51.2M.

Argenica Therapeutics's trades at 29.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Argenica Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Argenica Therapeutics and 10K+ public comps

Argenica Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $51.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Argenica Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Argenica Therapeutics Valuation Multiples

Argenica Therapeutics's NTM/LTM revenue growth is -100%

Argenica Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Argenica Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Argenica Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Argenica Therapeutics and other 10K+ public comps

Argenica Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 14% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Argenica Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Argenica Therapeutics M&A and Investment Activity

Argenica Therapeutics acquired  XXX companies to date.

Last acquisition by Argenica Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Argenica Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Argenica Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Argenica Therapeutics

When was Argenica Therapeutics founded? Argenica Therapeutics was founded in 2019.
Where is Argenica Therapeutics headquartered? Argenica Therapeutics is headquartered in Australia.
Is Argenica Therapeutics publicy listed? Yes, Argenica Therapeutics is a public company listed on ASX.
What is the stock symbol of Argenica Therapeutics? Argenica Therapeutics trades under AGN ticker.
When did Argenica Therapeutics go public? Argenica Therapeutics went public in 2021.
Who are competitors of Argenica Therapeutics? Similar companies to Argenica Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Argenica Therapeutics? Argenica Therapeutics's current market cap is $60.8M
What is the current revenue of Argenica Therapeutics? Argenica Therapeutics's last 12-month revenue is $1.8M.
What is the current EV/Revenue multiple of Argenica Therapeutics? Current revenue multiple of Argenica Therapeutics is 29.0x.
Is Argenica Therapeutics profitable? Yes, Argenica Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.